RBC Capital Maintains Verve Therapeutics(VERV.US) With Buy Rating, Cuts Target Price to $17

Moomoo NewsNov 6 13:32 ET · Ratings

J.P. Morgan Maintains Verve Therapeutics(VERV.US) With Hold Rating, Cuts Target Price to $23

Moomoo NewsNov 6 13:32 ET · Ratings

CCORF Maintains Verve Therapeutics(VERV.US) With Buy Rating, Raises Target Price to $32

Moomoo NewsNov 6 13:32 ET · Ratings

RBC Capital Adjusts Price Target on Verve Therapeutics to $17 From $20, Maintains Outperform, Speculative Risk Rating

MT NewswiresNov 6 10:59 ET · Ratings

Verve Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow JonesNov 6 09:30 ET · Ratings

Verve Therapeutics Analyst Ratings

BenzingaNov 6 09:18 ET · Ratings